Empagliflozin for the treatment of heart failure

Overview Empagliflozin was granted Breakthrough Therapy Designation following the publication of results from EMPEROR-Preserved, the first and currently only successful clinical trial in heart failure with preserved ejection fraction (HFpEF). Main Body Recently, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY)...

Read more